What Symbio does

Symbio is a US-based therapeutic-specialized contract research organization (CRO) focused exclusively on dermatology, aesthetics, gastroenterology, and inflammatory diseases. Founded in 2002 and headquartered in Port Jefferson, New York, the company delivers Phase I-IV clinical trial services for pharmaceutical, biotech, and medical device sponsors across 50+ countries. Services span clinical trial project management, site feasibility and startup, monitoring, medical monitoring by qualified M.D.s with 10+ years of experience, regulatory affairs, medical writing, data management, and biostatistics, offered under both full-service and functional service provider (FSP) engagement models. Symbio cites 650+ clinical trials spanning 85+ indications with 70+ FDA approvals as accumulated track record.

The business model is project-based professional services revenue from enterprise pharma and biotech sponsors, sourced through an enterprise field sales motion organized regionally across the US and EMEA & APAC, complemented by heavy presence at specialty conferences (AAD, EADV, OCT, EAACI, ACE, Dermatology Drug Development Summit). The group expanded materially in November 2023 when Symbio, LLC and its Dow Development Laboratories subsidiary merged with Proinnovera GmbH under ARCHIMED private equity sponsorship, adding European scale and a vertically integrated topical formulation development and cGMP manufacturing capability through the 23,000 sq ft Petaluma, California DDL facility. A September 2024 rebrand unified the group under the Symbio name, and the company subsequently opened a new Australia office and legal entity in 2025 to establish Asia-Pacific presence.

The customer base consists of enterprise pharma and biotech sponsors developing dermatology drugs (acne, psoriasis, atopic dermatitis, rosacea), aesthetics products (dermal fillers, neurotoxins, energy-based devices), gastroenterology therapies (IBD, celiac, eosinophilic GI disorders, IBS), and inflammatory disease treatments (urticaria, prurigo nodularis, atopic dermatitis). Pricing is quote-based and project-specific, tied to study scope, phase, geography, and therapeutic complexity, and is not publicly disclosed. Strategically, the value proposition combines domain depth and investigator/site relationships built over 20+ years with turnkey capability spanning formulation development through regulatory submission, supported by ancillary tax advantages such as the French Crédit d'Impôt Recherche (CIR) certification.

Name

Symbio

Legal name

Symbio Clinical Research GmbH

Website

https://symbioresearch.com

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

101–250 employees

Short description

Symbio is a therapeutic-specialized CRO delivering end-to-end Phase I-IV clinical trial services in dermatology, aesthetics, gastroenterology, and inflammation for enterprise pharmaceutical and biotech sponsors across 50+ countries, supplemented by in-house topical formulation manufacturing through its Dow Development Laboratories subsidiary.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Medical Writing & Regulatory Submission Support CROs (HLAGAAAG)

Keywords

• Clinical research services
• Contract research organization
• Dermatology clinical trials
• Topical formulation development
• Medical device studies

Headquarters

HQ city

Port Jefferson

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. CRO Services (Full-Service and FSP): End-to-end clinical trial solutions as a full-service CRO or functional service provider (FSP) for dermatology, aesthetics, gastroenterology, and inflammation drug and device development. Services include clinical trial project management, site feasibility and startup, monitoring, medical monitoring, regulatory affairs, medical writing, data management, biostatistics, and topical formulation development. Revenue is generated through service contracts with pharmaceutical and biotech sponsors.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

Symbio is a therapeutic-focused Contract Research Organization (CRO) that delivers end-to-end Phase I-IV clinical trial solutions for pharmaceutical and biotech sponsors in dermatology, aesthetics, gastroenterology, and inflammation. Services span clinical trial project management, site feasibility and startup, monitoring, medical monitoring, regulatory affairs, medical writing, data management, and biostatistics, delivered via full-service or functional service provider (FSP) models. Through its subsidiary Dow Development Laboratories (DDL), Symbio also provides turnkey topical drug product formulation design, development, and cGMP clinical supply manufacturing from a 23,000 sq ft FDA-registered facility in Northern California.

Product overview

Symbio is a therapeutic-focused Contract Research Organization (CRO) offering end-to-end clinical trial solutions through a unified platform. The portfolio consists of Symbio Clinical Research Services as the core CRO offering, complemented by Dow Development Laboratories (DDL) subsidiary for topical formulation development and manufacturing. Services span clinical trial project management, site feasibility and startup, monitoring, medical monitoring, regulatory affairs, medical writing, data management, and biostatistics. The company specializes in four therapeutic areas: dermatology, aesthetics, gastroenterology, and inflammation, supporting Phase I-IV drug and device trials globally.

Differentiator

Problem solved

Functional benefit

Brands

• Dow Development Laboratories (DDL): Subsidiary specializing in the design, development, and manufacture of topical drug products; FDA-registered and cGMP compliant
• Proinnovera

Products and services

• Symbio Clinical Research Services Full-service and Functional Service Provider (FSP) Contract Research Organization offering end-to-end Phase I-IV clinical trial solutions for pharmaceutical and biotech sponsors across dermatology, aesthetics, gastroenterology, and inflammation drug and device development globally.
• Dow Development Laboratories (DDL) — Topical Formulation Development & Manufacturing FDA-registered, cGMP-compliant subsidiary providing topical drug product formulation design, development, and manufacturing at a 23,000 sq ft facility in Petaluma, CA; supports IND, NDA, and ANDA programs for sponsors developing topical therapeutics.
• Dermatology Clinical Trials Specialized clinical trial management from formulation development through global trials to final approval for dermatology indications including acne, psoriasis, atopic dermatitis, rosacea, and rare skin diseases; full Phase I-IV delivery plus medical device studies for pharmaceutical and biotech sponsors.
• Aesthetics Clinical Trials Specialized clinical trials and regulatory support for aesthetic products including dermal fillers, neurotoxins, botulinum toxins, submental fat treatments, medical devices, energy-based aesthetic devices, and injectables; expertise in MDR Annex XVI and FDA regulatory requirements.
• Gastroenterology Clinical Trials Specialized gastroenterology clinical trials addressing patient recruitment for difficult populations, specialized endpoints, biomarker integration, and regulatory submissions across global markets; indications include IBD, celiac disease, eosinophilic GI disorders, and IBS.
• Inflammatory Disease Clinical Trials Specialized clinical trials for inflammatory diseases across dermatology, gastroenterology, and immunology indications; including urticaria, psoriasis, atopic dermatitis, prurigo nodularis, and rare inflammatory skin conditions; supports evolving therapeutic targets such as JAK inhibitors and biologics.

Quantifiable outcome

• 404 patients randomized in approximately 4.2 months with ~92% randomization rate and ~94% patient retention in a global Phase 3 psoriasis trial across 30 sites.
• +2 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Dow Development Laboratories (DDL)coreStrategic or Co-development PartnerDow Development Laboratories (DDL) is a subsidiary of Symbio, specializing in the design, development, and manufacture of topical drug products. DDL is FDA-registered and cGMP compliant, occupying a 23,000 sq ft custom-built facility in Petaluma, California. The subsidiary enables Symbio to provide an integrated turnkey solution covering topical formulation development, GLP studies, GMP clinical supply manufacturing, and clinical packaging and labeling.

Scale indicators7 records

Recent moves9 records

Expansion highlights5 records

Direct peers

• Worldwide Clinical Trials: Mid-size, therapeutically-focused CRO with strong expertise in dermatology, neuroscience, and cardiometabolic therapeutic areas. Directly comparable in business model (full-service and FSP), therapeutic specialization depth, and mid-size positioning competing for similar pharma/biotech sponsors.
• Medpace: Full-service CRO with strong therapeutic specialization and a high-touch operating model similar to Symbio's. Comparable in delivering Phase I-IV trials with focused therapeutic expertise and a reputation for operational excellence in specialty indications.
• CTI Clinical Trial & Consulting Services: Mid-size CRO with therapeutic specialization across multiple areas including dermatology and inflammation. Comparable in size, therapeutic focus, and full-service/FSP delivery model targeting similar pharma/biotech sponsors.
• Therapeutics Inc. Dermatology-focused CRO specializing in skin and aesthetics trials, providing Phase I-IV services. Directly comparable niche therapeutic specialization in dermatology with similar target sponsor base.
• Biorasi: Mid-size CRO with therapeutic focus areas including dermatology, oncology, and CNS. Comparable in size, therapeutic-area specialization strategy, and full-service delivery model for specialty pharma and biotech sponsors.

Broad incumbents

• ICON plc: One of the largest global CROs offering full-service Phase I-IV capabilities across all major therapeutic areas. Broad incumbent competing for dermatology trials at the top end of the market, with significantly greater scale and global reach than Symbio.
• IQVIA: World's largest CRO with comprehensive clinical research services across all therapeutic areas including dermatology. Broad incumbent whose dermatology practice competes with Symbio on large global trials with data, technology, and scale advantages.
• Parexel: Large global full-service CRO with therapeutic specialization including dermatology and inflammation. Competes with Symbio for full-service dermatology contracts with broader therapeutic coverage and larger scale.

Emerging players

• Clinipace Worldwide: Mid-size CRO offering full-service clinical research with therapeutic focus in oncology and other specialty areas. Comparable in size and operational model, with some therapeutic-area overlap relevant to Symbio's inflammation and gastroenterology practices.
• Caidya: Mid-size CRO formed from the merger of dMed and Clinipace, providing clinical development services across multiple therapeutic areas. Comparable in size and therapeutic focus strategy, with relevant overlap in specialty pharma trials.

Market position

Strengths1 record

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/symbioresearch
• Xx.com/SymbioResearch

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles23 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Symbio